| Original language | English (US) |
|---|---|
| Pages (from-to) | E203-E206 |
| Journal | American journal of hematology |
| Volume | 96 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of hematology, Vol. 96, No. 6, 01.06.2021, p. E203-E206.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The prognostic significance of del6q23 in chronic lymphocytic leukemia
AU - Audil, Hadiyah Y.
AU - Hampel, Paul J.
AU - Van Dyke, Daniel L
AU - Achenbach, Sara J.
AU - Rabe, Kari G.
AU - Smoley, Stephanie A.
AU - Call, Timothy George
AU - Ding, Wei
AU - Shi, Min
AU - Hanson, Curtis A
AU - Wang, Yucai
AU - Muchtar, Eli
AU - Koehler, Amber B.
AU - Schwager, Susan M.
AU - Leis, Jose F.
AU - Braggio, Esteban
AU - Slager, Susan L.
AU - Kay, Neil E.
AU - Kenderian, Saad S.
AU - Parikh, Sameer A.
N1 - Funding Information: Results of this study were presented in part at the 25th European Hematology Association Congress held virtually in June 2020. The conduct of this research was supported in part by the Henry J. Predolin Foundation. Sameer A. Parikh and Saad S. Kenderian also acknowledge support from the Mayo Clinic K2R Career Development Program. Funding Information: S.A.P.: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. He has also participated in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, and AbbVie (he was not personally compensated for his participation). N.E.K.: Research funding from: Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for: Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, Morpho‐Sys, Rigel Pharm and Juno Therapeutics. He is on an advisory Board for Astra Zeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. S.S.K.: S.S.K. is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen (through Mayo Clinic), Morphosys (through Mayo Clinic), Tolero (through Mayo Clinic), and Mettaforge (through Mayo Clinic). S.S.K. receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs and Lentigen. S.S.K. has participated in consultancy with Torque, Leahlabs, and Kiniksa. S.S.K. has participated in scientific advisory board meetings of Juno, Kite, and Humanigen, and data safety monitoring board meetings of Humanigen. W.D.: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). Y.W.: Research funding (to the institution) from Incyte, InnoCare, Norvatis, and Genentech. E.B.: E.B. is a consultant of DASA. All other authors declare no competing financial interests.
PY - 2021/6/1
Y1 - 2021/6/1
UR - https://www.scopus.com/pages/publications/85103681706
UR - https://www.scopus.com/pages/publications/85103681706#tab=citedBy
U2 - 10.1002/ajh.26168
DO - 10.1002/ajh.26168
M3 - Letter
C2 - 33749852
AN - SCOPUS:85103681706
SN - 0361-8609
VL - 96
SP - E203-E206
JO - American journal of hematology
JF - American journal of hematology
IS - 6
ER -